J F Vansteenkiste

Summary

Affiliation: Katholieke Universiteit Leuven
Country: Belgium

Publications

  1. pmc Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol
    Michael Kreuter
    Department of Medicine Thoracic Oncology, Thoraxklinik at the University of Heidelberg, Heidelberg, Germany
    BMC Cancer 7:77. 2007
  2. ncbi request reprint Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline
    J Vansteenkiste
    Respiratory Oncology Unit Pulmonology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Support Care Cancer 12:253-62. 2004
  3. ncbi request reprint Gefitinib (Iressa): a novel treatment for non-small cell lung cancer
    Johan Vansteenkiste
    Respiratory Oncology Unit University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Expert Rev Anticancer Ther 4:5-17. 2004
  4. ncbi request reprint Positron emission tomography in the management of non-small cell lung cancer
    Johan F Vansteenkiste
    Respiratory Oncology Unit, Department of Pulmonology, Leuven Lung Cancer Group, University Hospital Gasthuisberg, Catholic University, Herestraat 49, B 3000 Leuven, Belgium
    Hematol Oncol Clin North Am 18:269-88. 2004
  5. ncbi request reprint Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review
    Johan Vansteenkiste
    Clinical Trial Unit, Department of Pulmonology, University Hospital Gasthuisberg, Catholic University, Leuven, Belgium
    Lancet Oncol 5:531-40. 2004
  6. doi request reprint Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
    Johan Vansteenkiste
    Respiratory Oncology Unit Pulmonology, University Hospital Gasthuisberg, Herestraat 49, 3000, Leuven, Belgium
    Invest New Drugs 26:483-8. 2008
  7. ncbi request reprint The future of adjuvant chemotherapy for resected non-small cell lung cancer
    Johan F Vansteenkiste
    Respiratory Oncology Unit Pulmonology, Leuven Lung Cancer Group, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Expert Rev Anticancer Ther 5:165-75. 2005
  8. ncbi request reprint The use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia
    Johan Vansteenkiste
    University Hospital Gasthuisberg, Respiratory Oncology Unit Pulmonology, Herestraat 49, B 3000 Leuven, Belgium
    Expert Opin Pharmacother 6:429-40. 2005
  9. ncbi request reprint Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy
    Johan Vansteenkiste
    Respiratory Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    J Clin Oncol 25:3448-55. 2007
  10. ncbi request reprint Improving patient management in metastatic non-small cell lung cancer
    Johan Vansteenkiste
    Respiratory Oncology Unit Pulmonology and Leuven Lung Cancer Group, University Hospital Leuven, Herestraat 49, 3000 Leuven, Belgium
    Lung Cancer 57:S12-7. 2007

Collaborators

Detail Information

Publications66

  1. pmc Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol
    Michael Kreuter
    Department of Medicine Thoracic Oncology, Thoraxklinik at the University of Heidelberg, Heidelberg, Germany
    BMC Cancer 7:77. 2007
    ..Doublet regimens with pemetrexed, a multi-target folate inhibitor, and platin show clear activity in non-small cell lung cancer and are well tolerated with low toxicity rates and excellent delivery...
  2. ncbi request reprint Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline
    J Vansteenkiste
    Respiratory Oncology Unit Pulmonology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Support Care Cancer 12:253-62. 2004
    ..We report several analyses of data from a phase III trial of darbepoetin alfa versus placebo, comparing outcomes for patients with mild and moderate-to-severe anaemia...
  3. ncbi request reprint Gefitinib (Iressa): a novel treatment for non-small cell lung cancer
    Johan Vansteenkiste
    Respiratory Oncology Unit University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Expert Rev Anticancer Ther 4:5-17. 2004
    ..Gefitinib has also shown promising efficacy in other solid tumors that rely on EGFR-related mechanisms for growth and survival. This article reviews the profile of gefitinib and the evidence supporting its use in the treatment of NSCLC...
  4. ncbi request reprint Positron emission tomography in the management of non-small cell lung cancer
    Johan F Vansteenkiste
    Respiratory Oncology Unit, Department of Pulmonology, Leuven Lung Cancer Group, University Hospital Gasthuisberg, Catholic University, Herestraat 49, B 3000 Leuven, Belgium
    Hematol Oncol Clin North Am 18:269-88. 2004
    ....
  5. ncbi request reprint Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review
    Johan Vansteenkiste
    Clinical Trial Unit, Department of Pulmonology, University Hospital Gasthuisberg, Catholic University, Leuven, Belgium
    Lancet Oncol 5:531-40. 2004
    ..Good prospective evidence documents the effectiveness of [(18)F]FDG-PET over CT in the correct identification of recurrent lung cancer...
  6. doi request reprint Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
    Johan Vansteenkiste
    Respiratory Oncology Unit Pulmonology, University Hospital Gasthuisberg, Herestraat 49, 3000, Leuven, Belgium
    Invest New Drugs 26:483-8. 2008
    ..Vorinostat in a daily oral schedule for 14 days/3 weeks was tolerable at 200 mg bid only, and no responses were observed in this study. Most patients, however, had limited drug exposure which did not allow a reliable efficacy analysis...
  7. ncbi request reprint The future of adjuvant chemotherapy for resected non-small cell lung cancer
    Johan F Vansteenkiste
    Respiratory Oncology Unit Pulmonology, Leuven Lung Cancer Group, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Expert Rev Anticancer Ther 5:165-75. 2005
    ....
  8. ncbi request reprint The use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia
    Johan Vansteenkiste
    University Hospital Gasthuisberg, Respiratory Oncology Unit Pulmonology, Herestraat 49, B 3000 Leuven, Belgium
    Expert Opin Pharmacother 6:429-40. 2005
    ..Across all trials, darbepoetin alfa was shown to be a well-tolerated and safe therapy. The possible favourable effect on the outcome of cancer patients needs to be further elucidated...
  9. ncbi request reprint Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy
    Johan Vansteenkiste
    Respiratory Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    J Clin Oncol 25:3448-55. 2007
    ..This international, randomized, phase II trial assessed two administration schedules of ixabepilone as second-line therapy in patients with non-small-cell lung cancer (NSCLC)...
  10. ncbi request reprint Improving patient management in metastatic non-small cell lung cancer
    Johan Vansteenkiste
    Respiratory Oncology Unit Pulmonology and Leuven Lung Cancer Group, University Hospital Leuven, Herestraat 49, 3000 Leuven, Belgium
    Lung Cancer 57:S12-7. 2007
    ..The targeted therapy erlotinib is also being investigated in this setting. Further studies are required to establish the role of newer agents in the management of advanced NSCLC...
  11. ncbi request reprint Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management
    Johan F Vansteenkiste
    UZ Gasthuisberg, Catholic University of Leuven, Herestraat 49, 3000 Leuven, Belgium
    Cancer Treat Rev 32:S11-5. 2006
    ....
  12. ncbi request reprint Second-line therapeutic options in non-small-cell lung cancer
    Johan Vansteenkiste
    Respiratory Oncology Unit, Department of Pulmonology, University Hospital Leuven, Leuven Lung Cancer Group, Leuven, Belgium
    Lung Cancer 54:S15-8. 2006
    ..Therefore, current challenges include the identification of the most appropriate second-line regimen and determination of the best way to position this within a logical, evidence-based treatment sequence...
  13. ncbi request reprint Positron emission tomography in nonsmall cell lung cancer
    Johan Vansteenkiste
    Respiratory Oncology Unit, Department Pulmonology and Leuven Lung Cancer Group, University Hospital Gasthuisberg, Leuven, Belgium
    Curr Opin Oncol 19:78-83. 2007
    ..Established indications are the differential diagnosis of lung nodules, as well as mediastinal lymph node and extrathoracic staging...
  14. ncbi request reprint PET scan in lung cancer: current recommendations and innovation
    Johan F Vansteenkiste
    Department of Pulmonology, Respiratory Oncology Unit and PET Center Nuclear Medicine, Leuven Lung Cancer Group, Leuven, Belgium
    J Thorac Oncol 1:71-3. 2006
    ..Technical innovations, such as PET cameras with better spatial resolution, or new radiopharmaceutical probes to study applications of PET in molecular biology hold promise for future refinements in this field...
  15. ncbi request reprint Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals
    Johan Vansteenkiste
    University Hospital Gasthuisberg, Respiratory Oncology Unit Pulmonology, Herestraat 49, B 3000 Leuven, Belgium
    Expert Rev Anticancer Ther 7:1347-55. 2007
    ..Further studies focusing on survival as the primary end point are ongoing...
  16. ncbi request reprint Staging of lung cancer
    Jokke Wynants
    Respiratory Oncology Unit Pulmonology, Leuven Lung Cancer Group, University Hospital Gasthuisberg, Catholic University, Herestraat 49, B 3000, Leuven, Belgium
    Radiol Clin North Am 45:609-25, v. 2007
    ....
  17. ncbi request reprint Pharmacotherapy of chemotherapy-induced anaemia
    Johan Vansteenkiste
    Respiratory Oncology Unit Pulmonology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Expert Opin Pharmacother 4:2221-7. 2003
    ..Several forms of erythropoietic proteins are available in various regions of the world. Their characteristics, clinical evidence for use, guidelines for clinical administration and their safety are described in this review...
  18. ncbi request reprint PET scan in the staging of non-small cell lung cancer
    Johan F Vansteenkiste
    Respiratory Oncology Unit, Pulmonology, and Leuven Lung Cancer Group, Catholic University Leuven, Belgium
    Lung Cancer 42:S27-37. 2003
    ..In the meanwhile, a current recommendation for the use of PET in contemporary lung cancer staging is provided...
  19. ncbi request reprint Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia
    Johan Vansteenkiste
    Respiratory Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    Expert Opin Biol Ther 3:501-8. 2003
    ..Darbepoetin alfa has been shown to have safe clinical efficacy in a variety of tumour settings and with several types of chemotherapy...
  20. ncbi request reprint Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine
    J F Vansteenkiste
    University Hospital Gasthuisberg, Leuven, Belgium
    Ann Oncol 12:1221-30. 2001
    ..Clinical benefit response was the primary end-point of this prospective randomised trial in symptomatic, advanced stage IIIB/IV NSCLC, comparing single agent gemcitabine (GEM) to cisplatin-based chemotherapy...
  21. ncbi request reprint Practical approach to patients presenting with multiple synchronous suspect lung lesions: a reflection on the current TNM classification based on 54 cases with complete follow-up
    J F Vansteenkiste
    Respiratory Oncology Unit, Department of Pulmonology, University Hospital Gasthuisberg, Catholic University Leuven, Herestraat 49, B 3000 Leuven, Belgium
    Lung Cancer 34:169-75. 2001
    ....
  22. ncbi request reprint Gemcitabine plus etoposide in chemonaive extensive disease small-cell lung cancer: a multi-centre phase II study
    J Vansteenkiste
    Respiratory Oncology Unit, Univ Hosp Gasthuisberg, Leuven, Belgium
    Ann Oncol 12:835-40. 2001
    ..Therefore, a phase II trial was initiated to examine the activity and toxicity of this schedule in extensive disease SCLC...
  23. ncbi request reprint Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group
    J F Vansteenkiste
    Department of Pulmonology, Respiratory Oncology Unit, University Hospital Gasthuisberg, Catholic University, Leuven, Belgium
    J Clin Oncol 17:3201-6. 1999
    ..The Standardized Uptake Value (SUV), a semi-quantitative measurement of FDG uptake on positron emission tomography (PET) scan, could thus be of prognostic significance...
  24. ncbi request reprint Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group
    J F Vansteenkiste
    Department of Pulmonology Respiratory Oncology, University Hospital Gasthuisberg, Catholic Univesity Leuven, Belgium
    Ann Oncol 9:1193-8. 1998
    ..Based on our previous results with FDG-PET in the initial staging of N2 disease, we investigated whether PET after IC could be helpful in predicting MLN downstaging and therapeutic outcome...
  25. ncbi request reprint Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients
    J F Vansteenkiste
    Department of Pulmonology Respiratory Oncology Unit, University Hospital Gasthuisberg, Catholic University Leuven, Belgium
    J Clin Oncol 16:2142-9. 1998
    ....
  26. ncbi request reprint Vindesine-ifosfamide-platinum (VIP) induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective study. Leuven Lung Cancer Group
    J F Vansteenkiste
    Department of Pulmonology, University Hospital Gasthuisberg, Belgium
    Ann Oncol 9:261-7. 1998
    ..In this study, the efficacy and toxicity of three-drug VIP induction chemotherapy, the pathologic response in resection specimens, the early survival and relapse patterns are examined...
  27. ncbi request reprint Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: a review. The Leuven Lung Cancer Group
    J Vansteenkiste
    Department of Pulmonology, University Hospital Gasthuisberg, Catholic University, Leuven, Belgium
    Eur J Cardiothorac Surg 13:1-12. 1998
    ..Theoretical concepts suggest a beneficial role for preoperative induction treatment. The solidity of the therapeutic results with this approach in the currently available data is examined...
  28. ncbi request reprint Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: analysis of the literature
    J F Vansteenkiste
    Department of Pulmonology Respiratory Tumour Unit, University Hospital Gasthuisberg, Catholic University, Leuven, Belgium
    Lung Cancer 19:3-13. 1998
    ..Stratification for these prognostic factors could help in the planning of future trials on combined modality treatment in N2-NSCLC...
  29. ncbi request reprint Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group
    J F Vansteenkiste
    Department of Pulmonology Respiratory Tumor Unit, University Hospital Gasthuisberg, Catholic University Leuven, Belgium
    Ann Thorac Surg 63:1441-50. 1997
    ..The selection of stage IIIA N2 non-small cell lung cancer patients for primary surgical treatment remains controversial...
  30. ncbi request reprint Imaging in lung cancer: positron emission tomography scan
    J F Vansteenkiste
    Dept of Pulmonology, University Hospital Gasthuisberg, Catholic University, Leuven, Belgium
    Eur Respir J Suppl 35:49s-60s. 2002
    ..These techniques are promising for future use in very early response monitoring during chemo- or radiotherapy, in evaluation of novel molecular-targeted lung cancer therapies, or even gene therapy...
  31. ncbi request reprint Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy
    Johan Vansteenkiste
    Respiratory Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    J Natl Cancer Inst 94:1211-20. 2002
    ..This phase III study compared the safety and efficacy of darbepoetin alfa with placebo in patients with lung cancer receiving chemotherapy...
  32. ncbi request reprint Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine
    Johan Vansteenkiste
    Respiratory Oncology Unit Department of Pulmonology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Lung Cancer 40:191-9. 2003
    ..We now report the detailed individual symptom control analysis, and the influence of cisplatin-use, age, performance status (PS) and duration of treatment...
  33. ncbi request reprint Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations
    Johan Vansteenkiste
    Respiratory Oncology Unit Pulmonology, University Hospital Gasthuisberg, Leuven, Belgium
    Oncology (Williston Park) 16:45-55. 2002
    ..Darbepoetin alfa increased the likelihood of a hemoglobin response and decreased the need for transfusions in cancer patients with chemotherapy-induced anemia...
  34. doi request reprint Survival after trimodality treatment for superior sulcus and central T4 non-small cell lung cancer
    Paul De Leyn
    Department of Thoracic Surgery, University Hospitals and Leuven Lung Cancer Group, Leuven, Belgium
    J Thorac Oncol 4:62-8. 2009
    ..For sulcus superior tumors and central cT4 tumors, low resectability and poor long-term survival rates are obtained with single-modality treatment...
  35. ncbi request reprint The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology
    J F Vansteenkiste
    Respiratory Oncology Unit, Dept of Pulmonology, University Hospital Gasthuisberg, Catholic University Leuven, Belgium
    Eur Respir J 17:802-20. 2001
    ..Finally, a whole new field of application of positron emission tomography in molecular biology, using new radiopharmaceuticals, is under extensive investigation...
  36. ncbi request reprint Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer
    C A Dooms
    Respiratory Oncology Unit Pulmonology and Leuven Lung Cancer Group, Catholic University, Leuven, Belgium
    Eur Respir J 27:895-901. 2006
    ..The gains in subjective outcome achieved with palliative chemotherapy are critical from both a clinical and a health economic point of view...
  37. doi request reprint An unexpected abdominal 18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) in a patient with limited stage small cell lung cancer
    Lynn Decoster
    Respiratory Oncology Unit Pulmonology and Leuven Lung Cancer Group, University Hospital Gasthuisberg, Leuven, Belgium
    J Thorac Oncol 3:174-6. 2008
    ..Follow-up fusion positron emission tomography-computed tomography revealed an unusual SCLC complication...
  38. doi request reprint Impact of FDG-PET-induced treatment choices on long-term outcome in non-small cell lung cancer
    Isabelle Wauters
    Respiratory Oncology Unit Pulmonology and Leuven Lung Cancer Group, University Hospital Gasthuisberg, Catholic University, BE 3000 Leuven, Belgium
    Respiration 79:97-104. 2010
    ..Addition of FDG-PET to conventional staging (CS) improves accuracy, but few data have described the impact of this on long-term survival in relation to treatment...
  39. ncbi request reprint The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer
    Liesbet Schrevens
    Respiratory Oncology Unit Pulmonology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Oncologist 9:633-43. 2004
    ..However, at this time, PET does not replace conventional imaging. Large-scale randomized studies are currently examining whether PET staging will actually improve the appearance of lung cancer outcome...
  40. doi request reprint Image of the month. Rash in a patient treated with pemetrexed for relapsed non-small cell lung cancer
    Isabelle Declercq
    Respiratory Oncology Unit Pulmonology and Leuven Lung Cancer Group, University Hospital Gasthuisberg, Leuven, Belgium
    J Thorac Oncol 3:662-3. 2008
  41. doi request reprint Unexpected slight fluorodeoxyglucose-uptake on positron emission tomography in a pulmonary hamartoma
    Ulrike Himpe
    Respiratory Oncology Unit Pulmonology and Leuven Lung Cancer Group, University Hospital Gasthuisberg, Leuven, Belgium
    J Thorac Oncol 4:107-8. 2009
    ..Because of the risk for retro-obstructive pneumonia, and because there was a small increase in diameter of the lesion on CT, thoracotomy was proposed. Pathologic examination revealed a surprising and rare finding...
  42. doi request reprint Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival
    Herbert Decaluwe
    Leuven Lung Cancer Group, Department of Thoracic Surgery, University Hospital Leuven, Leuven, Belgium
    Eur J Cardiothorac Surg 36:433-9. 2009
    ..Analysis of single centre results and identification of prognostic factors of surgical combined modality treatment in pathological proven stage IIIA-N2 non-small cell lung cancer (NSCLC)...
  43. doi request reprint Biological correlates of the maximum 18-fluoro-2-deoxy-glucose uptake on positron emission tomography in non-small cell lung carcinoma after induction chemotherapy
    Christophe Dooms
    Department of Pulmonology and Leuven Lung Cancer Group, University Hospital Gasthuisberg, Leuven, Belgium
    J Thorac Oncol 4:1221-5. 2009
    ..We aimed to investigate the mechanisms that drive persistent FDG uptake in non-small cell lung carcinoma treated with IC...
  44. doi request reprint Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer
    Christophe Dooms
    Department of Pulmonology and Leuven Lung Cancer Group, University Hospitals Leuven, Belgium
    J Thorac Oncol 4:822-8. 2009
    ..We assessed the in vivo FDG uptake, measured as maximum pixel standardized uptake value (SUVmax), in stages I and II NSCLC for its prognostic value and association with in vitro quantitative morphology of tumor vitality...
  45. pmc Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial
    Johan Vansteenkiste
    Respiratory Oncology Unit Pulmonology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    BMC Cancer 9:311. 2009
    ..In the European Union and United States, ESA therapy initiation for CIA is now recommended at a Hb level < or = 10 g/dL. The present exploratory analysis examined how ESA initiation at this Hb level may impact patient care...
  46. ncbi request reprint Interstitial lung diseases: characteristics at diagnosis and mortality risk assessment
    Michiel J Thomeer
    Department of Respiratory Medicine, Universitaire Ziekenhuizen Leuven, Afdeling Longziekten, Herestraat 49, Leuven B 3000, Belgium
    Respir Med 98:567-73. 2004
    ..A Cox regression analysis showed that type of ILD, FVC, age at diagnosis and % of macrophages in BALF predict outcome of patients affected by ILD...
  47. ncbi request reprint Value of FDG-PET in the management of non-small cell lung cancer
    Sigrid Stroobants
    Department of Nuclear Medicine, University Hospital Gasthuisberg, Leuven, Belgium
    Eur J Radiol 45:49-59. 2003
    ..Emphasis is put on the potential clinical implementation of the numerous data of the last decade...
  48. ncbi request reprint Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage II
    Paul De Leyn
    Department of Thoracic Surgery, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium
    J Clin Oncol 24:3333-9. 2006
    ....
  49. ncbi request reprint Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer
    Johan Vansteenkiste
    Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
    Invest New Drugs 23:263-9. 2005
    ..The present study did not show any advantage, in response rate or secondary endpoints, with aprinocarsen; however, the toxicity was not unduly increased, and aprinocarsen regimen was safely administered...
  50. doi request reprint Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose po
    Christophe Dooms
    Department of Pulmonology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    J Clin Oncol 26:1128-34. 2008
    ..We created a data-based restaging strategy combining morphometric tissue analysis of mediastinal lymph nodes (LNs) and 18-fluoro-2-deoxy-glucose positron emission tomography (FDG-PET) response monitoring in the primary tumor...
  51. doi request reprint Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development
    L Decoster
    Leuven Lung Cancer Group, University Hospital Gasthuisberg, Leuven, Belgium
    Ann Oncol 23:1387-93. 2012
    ..Mode of action, development, available clinical data, and currently ongoing phase III studies are reviewed...
  52. doi request reprint Systematic review of symptom control and quality of life in studies on chemotherapy for advanced non-small cell lung cancer: how CONSORTed are the data?
    Karin Pat
    Respiratory Oncology Unit Department of Pulmonology and Leuven Lung Cancer Group, University Hospital Gasthuisberg, Leuven, Belgium
    Lung Cancer 62:126-38. 2008
    ..The aim of this report was to analyse to what extent the different RCTs with information on PRO's adhere to the CONSORT statement...
  53. ncbi request reprint Clinical-radiological presentation and outcome of surgically treated pulmonary carcinoid tumours: a long-term single institution experience
    Liesbet Schrevens
    Respiratory Oncology Unit Pulmonology, Leuven Lung Cancer Group, Catholic University, Leuven, Belgium
    Lung Cancer 43:39-45. 2004
    ..To determine the presenting features and the outcome of surgically treated pulmonary carcinoid tumours...
  54. ncbi request reprint Darbepoetin alfa in the treatment of chemotherapy-induced anaemia
    Isabelle Wauters
    Catholic University, University Hospital Gasthuisberg, Respiratory Oncology Unit Pulmonology and Leuven Lung Cancer Group, Herestraat 49, B 3000 Leuven, Belgium
    Expert Opin Biol Ther 9:221-30. 2009
    ..After its initial development for anaemia due to renal insufficiency, an extensive clinical trial program has defined its role in cancer patients...
  55. doi request reprint Survival after resection of synchronous bilateral lung cancer
    Paul De Leyn
    Department of Thoracic Surgery, University Hospitals and Leuven Lung Cancer Group, Herestraat 49, 3000 Leuven, Belgium
    Eur J Cardiothorac Surg 34:1215-22. 2008
    ..In this retrospective study, the survival after resection of synchronous bilateral lung cancer is evaluated...
  56. ncbi request reprint Positron emission tomography in nonsmall cell lung cancer
    Christophe Dooms
    Respiratory Oncology Unit Pulmonology and Leuven Lung Cancer Group, University Hospital Gasthuisberg, Leuven, Belgium
    Curr Opin Pulm Med 13:256-60. 2007
    ..We review recent developments with the emphasis on impact of positron emission tomography in early diagnosis, staging, restaging and prognosis of nonsmall cell lung cancer...
  57. ncbi request reprint Mediastinal emphysema and small cell lung cancer (SCLC): a case-report
    Christophe Libeer
    Department of Pulmonology, Respiratory Oncology Unit, University Hospital Gasthuisberg, Catholic University Leuven, Herestraat 49, B 3000 Leuven, Belgium
    Lung Cancer 47:139-42. 2005
    ..The occurrence of spontaneous mediastinal emphysema in patients with small cell lung cancer has rarely been described in the literature...
  58. ncbi request reprint Seeking a home for a PET, part 3: Emerging applications of positron emission tomography imaging in the management of patients with lung cancer
    Frank C Detterbeck
    Division of Cardiothoracic Surgery, Medical School Wing C Room 354, CB 7065, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7065, USA
    Chest 126:1656-66. 2004
    ..Further technologic improvements in PET scanners are likely to bring further benefits to the management of patients with lung cancer in the future...
  59. doi request reprint Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide
    Robert Pirker
    Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    J Clin Oncol 26:2342-9. 2008
    ....
  60. ncbi request reprint FDG-PET for lymph node staging in NSCLC: a major step forward, but beware of the pitfalls
    Johan F Vansteenkiste
    Lung Cancer 47:151-3. 2005
  61. ncbi request reprint Nodules, CT-scans and PET-scans: a good partnership
    Johan F Vansteenkiste
    Lung Cancer 45:29-30. 2004
  62. ncbi request reprint The effect of chemotherapy on symptom control and quality of life in patients with advanced non-small cell lung cancer
    Christophe A Dooms
    University Hospital Gasthuisberg, Respiratory Oncology Unit, Dept of Pulmonology, Herestraat 49, B 3000 Leuven, Belgium
    Expert Rev Anticancer Ther 6:531-44. 2006
    ..Future randomized studies should take up the challenge of looking at the patients' benefit as a primary end point...
  63. ncbi request reprint Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission tomography
    Corneline J Hoekstra
    Clinical PET Centre and Departments of Pulmonary Medicine, VU University Medical Centre, 1007 MB Amsterdam, The Netherlands
    Clin Cancer Res 8:2109-15. 2002
    ..The objective of the present study was to assess whether it is feasible to measure perfusion in vivo in non-small cell lung cancer (NSCLC) using H(2)(15)O and positron emission tomography...
  64. doi request reprint Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia
    Laurent Bastit
    Centre Frédéric Joliot, Rouen, France
    J Clin Oncol 26:1611-8. 2008
    ..This study was designed to evaluate the efficacy and safety of darbepoetin alpha given with IV iron versus with local standard practice (oral iron or no iron)...
  65. ncbi request reprint Endobronchial ultrasonography in bronchoscopic occult pulmonary lesions
    Christophe A Dooms
    Department of Pulmonology Respiratory Oncology Unit and Leuven Lung Cancer Group, Catholic University, Leuven, Belgium
    J Thorac Oncol 2:121-4. 2007
    ..Endobronchial ultrasonography (EBUS) has been reported to help localize a bronchoscopic occult pulmonary lesion and thereby improve the diagnostic yield of transbronchial biopsy (TBB)...